PHENEX PHARMACEUTICALS AG

Translating Science into Medicines

Phenex Pharmaceuticals AG was founded in 2002. It is a privately owned drug discovery & development company based in the Biotech Cluster Rhine-Neckar in Heidelberg.

Our company focuses its small-molecule drug discovery expertise in Liver diseases and in Cancer. Our aim is to translate novel scientific findings into best-in-class therapies that change current therapeutic regimens.

The most advanced novel drug, Cilofexor, is currently in phase 2 clinical development by Gilead Sciences, to whom we sold this program in 2014.

NEWS

April 5, 2019 in News

Phenex collaborates with Mathias Heikenwälder ́s research group from DKFZ

The biotech company and Prof. Dr. Heikenwälder see common ground for joint research projects in NASH and cancer metabolism Ludwigshafen, Germany, April 5, 2019 "I am intrigued by the level…
Read More
July 10, 2017 in News

Phenex AG announces milestone payment from Janssen for the entry of RORγt inhibitor into Phase I

Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations Ludwigshafen, Germany, July 10, 2017 "This recently achieved development milestone underlines the success of…
Read More

OUR R&D PROGRAMS

LXR / NASH

Cancer Metabolism

AHR / IDO Cancer

About Phenex

UPCOMING EVENTS – MEET US

ESMO Congress 2019

September 27 - October 1, Barcelona, Spain